Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ALNY vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALNY Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ALNY Overall Winner 6-Pillar Tally: ALNY 3 – 3 MRNA Matrix Metrics: ALNY 6 – 4 MRNA

As of Nov 20, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ALNY carries a Unified Composite Score of 48.8/100 (HOLD) at $143.82 (14.5x Forward P/E, 19.5% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).

  • Technical & Structure Timing Caution: ALNY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALNY vs MRNA
ALNY NASDAQ Head-to-Head Winner
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$143.82
-2.71% 1D
Market Cap $19.8B
TTM Revenue $5.01B
Forward P/E 14.5x
Beta / 30D Vol 0.54β · 94% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $168.22 · SMA50: $208.79
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (ALNY 3 – 3 MRNA)

Columns: Metric · ALNY · MRNA
1. Valuation Multiples ALNY
Forward P/E 14.5x 23.0x
Trailing P/E 7.5x 23.0x
PEG Ratio 0.20x N/M
EV / Revenue 3.9x 33.1x
2. Growth & Scale MRNA
Revenue Growth (YoY) +16.7% +29.2%
Earnings Growth (YoY) +633.5% -85.1%
TTM Revenue (USD) $5.01B $2.52B
Market Cap $19.8B $80.7B
3. Profitability & Quality ALNY
Gross Margin 77.3% -42.0%
Operating Margin 19.5% -80.8%
Net Profit Margin 52.8% -110.5%
Return on Equity (ROE) 138.1% -34.5%
4. Balance Sheet & Cash Flow ALNY
Cash Generation (TTM) $752M -$2.04B
Cash Flow Margin 15.0% -81.0%
Net Cash / Leverage $492M Net Cash $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 61.4% (23rd %ile) 89.6% (52nd %ile)
Put/Call OI Skew 1.27x (Put-Skewed) 1.05x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 57.8% of Rev ($2.90B) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALNY (6) vs MRNA (4)
Institutional Metric ALNY MRNA Criterion Row Edge
Market Capitalization
Scale
$19.8B $80.7B Larger Scale MRNA
Trailing P/E Ratio
Valuation
7.5x 23.0x Lower Multiple ALNY
Forward P/E Ratio
Valuation
14.5x 23.0x Lower Multiple ALNY
Revenue Growth (YoY)
Growth
+16.7% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
19.5% -80.8% Higher Margin ALNY
Net Profit Margin
Profitability
52.8% -110.5% Higher Margin ALNY
Return on Equity (ROE)
Capital Efficiency
138.1% -34.5% Higher ROE ALNY
52-Week Range Position
Momentum
0% ($143–$477) 67% ($22–$281) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
0.54β · 94% Vol 2.23β · 78% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
48.8 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite ALNY
Trailing 12M Revenue (USD)
Operating Scale
$5.01B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.3% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.20x PEG · 3.9x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$752M ($492M Net Cash) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +32.95 pp
ALNY: -36.72% · MRNA: -3.77%
3M Horizon MRNA +79.46 pp
ALNY: -39.06% · MRNA: +40.4%
6M Horizon MRNA +367.61 pp
ALNY: -51.65% · MRNA: +315.96%
1Y Horizon MRNA +775.24 pp
ALNY: -68.79% · MRNA: +706.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ALNY Revenue MRNA Revenue ALNY Op. Margin MRNA Op. Margin Margin Leader
FY2018 $70M $140M -1087.6% -306.0% MRNA
FY2019 $220M $60M -427.5% -906.8% ALNY
FY2020 $490M $800M -168.1% -95.0% MRNA
FY2021 $840M $18.5B -83.9% 72.0% MRNA
FY2022 $1.04B $19.3B -75.7% 48.9% MRNA
FY2023 $1.83B $6.85B -15.4% -61.9% ALNY
FY2024 $2.25B $3.24B -7.9% -121.9% ALNY
FY2025 $3.71B $1.94B 13.5% -158.1% ALNY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALNY BREAKDOWN
56d in phase · OBV DISTRIBUTION
Current IV 61.4%
IV Percentile 23rd %ile
Put/Call OI Skew 1.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ALNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $159.73 · IV 50.9%

ALNY vs. MRNA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of ALNY ($15,973) vs. MRNA ($21,527) against risk-defined 5-day vertical and put-wall option structures.

ALNY Spot $159.73 · IV 50.9%
ALNY Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $165 / $180 Bull Call Spread

Buy 1x $165C · Sell 1x $180C · 32d

Net Entry $395 Debit
T+5d @ +5% Move +$161 (+41%)
Max Risk / Buffer $395 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $145 / $135 Bull Put Spread

Sell 1x $145P · Buy 1x $135P · 32d

Net Entry $165 Credit
Max Credit / Yield +$165 (+19.8% RoM)
Max Risk / Buffer -10.3% Cushion ($835 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →
MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALNY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $19.8B market capitalization and 19.5% operating margin.
OpEx & R&D Reinvestment 57.8% of Rev ($2.90B)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ ALNY vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ALNY carries a Unified Composite Score of 48.8/100 (HOLD) at $143.82 (14.5x Forward P/E, 19.5% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Technical & Structure Timing Caution: ALNY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6); meanwhile MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRNA leads the Growth & Scale pillar: ALNY posts +16.7% YoY revenue growth and +633.5% YoY earnings growth on $5.01B TTM revenue (77.3% gross margin, 19.5% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ALNY cumulative revenue shifted +5200.0% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, ALNY deploys 57.8% of Rev ($2.90B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

ALNY screens cheaper on headline valuation multiples. ALNY trades at 14.5x Forward P/E, 7.5x Trailing P/E, 0.20x PEG, and 3.9x EV/Revenue (15.0% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALNY (138.1% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ALNY carries 61.4% implied volatility (23rd %ile, Compressed (<25th %ile)), a 1.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.54β · 94% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.